Journal
CURRENT OPINION IN PHARMACOLOGY
Volume 40, Issue -, Pages 74-80Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.coph.2018.03.009
Keywords
-
Categories
Funding
- Arthritis Research UK [19667, 20050, 20775, 20865, 21156]
- Medical Research Council [MR/1,020211/1, MR/L022893/1]
- Medical Research Council [MR/L020211/1] Funding Source: researchfish
- Versus Arthritis [20775, 20050, 19667] Funding Source: researchfish
- MRC [MR/L022893/1, MR/L020211/1] Funding Source: UKRI
Ask authors/readers for more resources
The gold standard cell therapy for repair of articular cartilage defects is autologous chondrocyte implantation, with good outcomes long-term. Mesenchymal stromal/stem cells (MSCs) from bone marrow or connective tissues such as fat are being pursued as alternatives for cartilage repair, and are trialled via intra-articular administration in patients with knee osteoarthritis. Early-phase clinical studies concur on safety and provide some promising insight into efficacy, but the mechanism of action remains unclear. Recent studies implicate extracellular vesicles as important mediators of MSC action, offering exciting therapeutic prospects. Our increasing understanding of the mechanisms underlying intrinsic articular cartilage maintenance and repair fosters hope that novel/ repurposed therapeutics could elicit repair through activation of endogenous stem/progenitor cells to maintain healthy joints and prevent osteoarthritis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available